

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6738432

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
THE MEDICINES COMPANY	06/21/2016
RECEIVING PARTY DATA	
Name:	CHIESI FARMACEUTICI S.P.A.
Street Address:	VIA PALERMO, 26/A
City:	PARMA
State/Country:	ITALY
Postal Code:	43122
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15892070
CORRESPONDENCE DATA	
Fax Number:	(412)904-7800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	412-904-7686
Email:	vorys_docketing@cardinal-ip.com
Correspondent Name:	VORYS, SATER, SEYMOUR AND PEASE LLP
Address Line 1:	500 GRANT STREET
Address Line 2:	SUITE 4900
Address Line 4:	PITTSBURGH, PENNSYLVANIA 15219
ATTORNEY DOCKET NUMBER:	074592-000365
NAME OF SUBMITTER:	MARYELLEN FEEHERY HANK
SIGNATURE:	/Maryellen Feehery Hank/
DATE SIGNED:	06/01/2021
Total Attachments: 14	
source=assign tmc#page1.tif	
source=assign tmc#page2.tif	
source=assign tmc#page3.tif	
source=assign tmc#page4.tif	
source=assign tmc#page5.tif	

source=assign tmc#page6.tif
source=assign tmc#page7.tif
source=assign tmc#page8.tif
source=assign tmc#page9.tif
source=assign tmc#page10.tif
source=assign tmc#page11.tif
source=assign tmc#page12.tif
source=assign tmc#page13.tif
source=assign tmc#page14.tif

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT dated as of June 21, 2016 (this "Assignment") is by and among The Medicines Company, a Delaware corporation ("Seller Parent" or "Assignor"), and Chiesi Farmaceutici S.p.A., a private limited company organized under the Laws of Italy ("Assignee").

WITNESSETH:

WHEREAS, Seller Parent, Assignee, and, solely for purposes of Article VII thereof, Chiesi USA, Inc., a Delaware corporation, have entered into a Purchase and Sale Agreement, dated as of May 9, 2016 (the "Purchase Agreement"), pursuant to which, among other things, Seller Parent has agreed to sell or cause to be sold certain assets to Assignee (and/or one or more of its designated Subsidiaries), as more fully described in the Purchase Agreement and upon the terms and conditions set forth therein; and

WHEREAS, pursuant to the Purchase Agreement, Assignor wishes to assign to Assignee, and Assignee wishes to assume from Assignor, the Patents set forth on Schedule A.

NOW, THEREFORE, in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms and subject to the conditions set forth herein, the parties hereto hereby agree as follows:

1. Definitions. Capitalized terms used but not defined herein shall have the respective meanings ascribed to them in the Purchase Agreement.

2. Assignment. Assignor does hereby irrevocably and unconditionally grant, sell, transfer, convey, assign and deliver to Assignee all of Assignor's right, title and interest in and to the Patents set forth on Schedule A, together with all rights and remedies related to infringement thereof and rights to protection of interests related thereto under all applicable laws. Assignor does further consent to the recordation of this Assignment by Assignee with the United States Patent and Trademark Office.

3. Further Assurances. Assignee shall be solely responsible for all actions and all costs whatsoever, including attorney's fees, arising after the date hereof and associated with the prosecution and the maintenance of the Patents set forth on Schedule A, and Assignor shall have no obligation to pay any prosecution costs and/or maintenance fees which become due for the Patents after the date hereof. Assignee shall be responsible for preparing and translating any documents that Assignee records to perfect its right, title and interest in the Patents set forth on Schedule A in any jurisdiction and all costs and fees associated with such recordation documents.

4. No Modification of the Purchase Agreement. Nothing contained herein shall release Seller Parent or Assignee from any of their respective obligations under the Purchase Agreement or in any way supersede, enlarge, diminish, limit, amend or modify any of the representations, warranties, indemnities, covenants or agreements of such parties set forth in the Purchase Agreement. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement shall govern.

5. General Provisions. Sections 1.2, 5.10, 13.1, 13.4, 13.5, 13.7, 13.8, 13.9, 13.10, 13.11, 13.13, 13.14 and 13.15 of the Purchase Agreement are each hereby incorporated by reference herein *mutatis mutandis*.

[Signature Page Follows]

IN WITNESS WHEREOF, each of Assignor and Assignee have caused this instrument to be signed by its proper and duly authorized officer as of the date and year first written above.

THE MEDICINES COMPANY

By: 

Name: Stephen M. Rodin
Title: Executive Vice President
and General Counsel

[Signature Page to Patent Assignment (Chiesi Farmaceutici S.p.A.)]

PATENT
REEL: 056401 FRAME: 0744

IN WITNESS WHEREOF, each of Assignor and Assignee have caused this instrument to be signed by its proper and duly authorized officer as of the date and year first written above.

CHIESI FARMACEUTICI S.P.A.

By: 
Name: Giacomo Chiesi
Title: Director

[Signature Page to Patent Assignment (Chiesi Farmaceutici S.p.A.)]

PATENT
REEL: 056401 FRAME: 0745

Schedule A

Kengreal Patents, Registrations and Patent Applications:

MDCO Ref.	Title	Country	Appln. No.	Status
MDCO-71PRO	Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same	US	62/103,136	Expired
MDCO-71WO	Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same	PCT	PCT/US15/39975	Pending
MDCO-71US	Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same	US	14/796,368	Issued
MDCO-71US2	Pharmaceutical Formulations Comprising High Purity Cangrelor and Methods for Preparing and Using the Same	US	15/049,727	Pending
MDCO-19	Method of Treatment, PCI Indication	US	61/260,361	Expired
MDCO-19	Method of Treatment, PCI Indication	US	12/943,717 US2011/0112030	Pending
MDCO-19	Method of Treatment, PCI Indication	PCT	PCT/US10/56225 WO2011/060066	Expired
MDCO-19	Method of Treatment, PCI Indication	AU	2010319612	Allowed
MDCO-19	Method of Treatment, PCI Indication	BR	BR112012011298-8	Pending
MDCO-19	Method of Treatment, PCI Indication	CA	2,778,880	Pending
MDCO-19	Method of Treatment, PCI Indication	EA	201270617	Pending
MDCO-19	Method of Treatment, PCI Indication	EP	10830654.9 EP2498731	Pending
MDCO-19	Method of Treatment, PCI Indication	US	13/792,056 US2013/0190265	Pending
MDCO-19	Method of Treatment, PCI Indication	PCT	PCT/US13/30081 WO 2014/142780	Expired
MDCO-19	Method of Treatment, PCI Indication	US	61/815,735	Expired
MDCO-19	Method of Treatment, PCI Indication	US	13/904,778	Issued
MDCO-19	Method of Treatment, PCI Indication	PCT	PCT/US13/43136	Expired
MDCO-19	Method of Treatment, PCI Indication	AU	2013381855	Pending
MDCO-19	Method of Treatment, PCI Indication	BR	BR112015022070-5	Pending
MDCO-19	Method of Treatment, PCI Indication	CA	2,904,523	Pending
MDCO-19	Method of Treatment, PCI Indication	CN	201380076382.X	Pending
MDCO-19	Method of Treatment, PCI Indication	EA	201591683	Pending
MDCO-19	Method of Treatment, PCI Indication	EP	13878203.2 EP 2964233	Pending
MDCO-19	Method of Treatment, PCI Indication	IN	04508/DELMP/2015	Pending
MDCO-19	Method of Treatment, PCI Indication	US	14/050,266 US 2014/0107032	Pending
MDCO-19	Method of Treatment, PCI Indication	PCT	PCT/US14/59972 WO 2015/054542	To be abandoned
MDCO-01	Method of Treatment, Bridge	PCT	PCT/US09/43820	Expired

			WG2009/140407	
MDCO-01	Method of Treatment, Bridge	US	12/990,332 US2011/0288043	Issued
MDCO-01	Method of Treatment, Bridge	AU	2009246396	Issued
MDCO-01	Method of Treatment, Bridge	BR	PI0912693.7	Pending
MDCO-01	Method of Treatment, Bridge	CA	2,724,470	Pending
MDCO-01	Method of Treatment, Bridge	CN	2.09801E+11	Abandoned
MDCO-01	Method of Treatment, Bridge	EP	9747490.2 EP2276541	Allowed
MDCO-01	Method of Treatment, Bridge	IN	282/D/ELNP/2010	Pending
MDCO-01	Method of Treatment, Bridge	JP	2011-509659	Issued
MDCO-01	Method of Treatment, Bridge	JP	2013-260851	Abandoned
MDCO-01	Method of Treatment, Bridge	US	13/209,271 US2012/0141468	Abandoned
MDCO-01	Method of Treatment, Bridge	PCT	PCT/US12/0502 83 WO2013/02547 6	Expired
MDCO-01	Method of Treatment, Bridge	AU	2012295343	Allowed
MDCO-01	Method of Treatment, Bridge	CA	2,844,931	Pending
MDCO-01	Method of Treatment, Bridge	EP	12824414.2 EP2276541	Pending
MDCO-01	Method of Treatment, Bridge	US	13/931,287 US2013/0303477	Abandoned
MDCO-01	Method of Treatment, Bridge	PCT	PCT/US13/48735 WO 2014/209389	Expired
MDCO-01	Method of Treatment, Bridge	US	13/954,821 US2013/0316968	Issued
MDCO-01	Method of Treatment, Bridge	US	14/195,798 US2015/0038449	Pending
MDCO-01	Method of Treatment, Bridge	US	14/269,429 US2015/0099716	Allowed
MDCO-19	Method of Treatment, Transition Dose	US	13/931,384 US2013/0303478	Issued
MDCO-19	Method of Treatment, Transition Dose	PCT	PCT/US13/48741 WO 2014/163656	Expired (National stage filed in AU, BR, CA, CN, EP, Eurasia, IN, JP)
MDCO-19	Method of Treatment, Transition Dose	US	13/954,843 US2013/0324492	Abandoned
MDCO-66	Method of Treatment, Pulmonary Hypertension	US	61/441,081	Expired
MDCO-66	Method of Treatment, Pulmonary Hypertension	PCT	PCT/US12/24411 WO2012/109406	Expired
MDCO-66	Method of Treatment, Pulmonary Hypertension	AU	2012214396	Pending
MDCO-66	Method of Treatment, Pulmonary Hypertension	BR	BR112013020377- 3	Pending

MDCO-66	Method of Treatment, Pulmonary Hypertension	CA	2,827,154	Pending
MDCO-66	Method of Treatment, Pulmonary Hypertension	CN	2,0128E+11	Allowed
MDCO-66	Method of Treatment, Pulmonary Hypertension	EP	12704620.9	Allowed
MDCO-66	Method of Treatment, Pulmonary Hypertension	IN	2675/KOLNP/2013	Pending
MDCO-66	Method of Treatment, Pulmonary Hypertension	JP	2013-553535	Pending
MDCO-66	Method of Treatment, Pulmonary Hypertension	RU	2013140793	Pending
MDCO-66	Method of Treatment, Pulmonary Hypertension	US	13/963,771	Abandoned
MDCO-66	Method of Treatment, Pulmonary Hypertension	US	15/004,880	Pending

Cleviprex Patents, Registrations and Patent Applications:

Reference No.	Title	Country	App. No.	Filing Date	Status
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Eurasian Patent Convention	201170287	07/30/2009	Abandoned
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Japan	2011-521123	07/30/2009	Pending (under appeal)
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Mexico	MX/a/2011/001341	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	United States	12/462,147	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Patent Cooperation Treaty	PCT/US09/04399	07/30/2009	Expired
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	China P.R.	200980138961.6	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Australia	2009277100	07/30/2009	Issued
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	United States	13/600,083	08/30/2012	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	United States	61/093,768	09/03/2008	Expired
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Brazil	PI0917562.8	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	India	1375/DELNP/2011	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	United Arab Emirates	113/2011	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	European Patent Convention	09803270.9	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	South Korea	2011-7004355	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	New Zealand	591304	07/30/2009	Issued
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Japan	2015-010907	01/23/2015	Pending
MDCO-03	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR STABILIZING THE SAME	United States	61,085,594	08/01/2008	Expired
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Canada	2,732,692	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	Egypt	199/2011	07/30/2009	Pending
MDCO-03	Pharmaceutical Compositions and Methods for Stabilizing the Same	United States	61/093,810	09/03/2008	Expired
MDCO-06	Pharmaceutical Compositions and Methods For Producing Low Impurity	Austria	09803550.4	07/29/2009	Issued

	Concentrations Of The Same				
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Belgium	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Bulgaria	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Cyprus	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Czech Republic	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Denmark	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Ireland	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Estonia	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Finland	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	France	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Germany	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Greece	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Hungary	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Iceland	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Italy	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Latvia	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Lithuania	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Luxembourg	09803550.4	07/29/2009	Issued

MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Maccedonia	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Malta	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Monaco	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Netherland	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Norway	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Eurasian Patent Convention	201170289	07/29/2009	Issued (RU entered)
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Japan	2011-521291	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Mexico	MX/a/2011/601240	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions and Methods for Producing Low Impurity Concentrations of The Same	India	1315/CHENB/2011	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	United States	13/511,631	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Patent Cooperation Treaty	PC/T/US09/52127	07/29/2009	Expired
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Egypt	198/2011	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	European Patent Convention	14150954.7	07/29/2009	Abandoned
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	United States	13/609,856	08/30/2012	Abandoned
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	South Korea	10-2011-7004358	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions and Methods for Producing Low Impurity Concentrations of The Same	United Arab Emirates	114/2011	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	European Patent Convention	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity	Canada	2,732,760	07/29/2009	Pending

	Concentrations Of The Same				
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	New Zealand	591205	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	United States	61085,597	08/01/2008	Expired
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Australia	2609276560	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Brazil	PI0916936,9	07/29/2009	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	China P.R.	200980139203,6	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	United States	13/919,893	06/17/2013	Pending
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	United States	61/093,772	09/03/2008	Expired
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Poland	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Portugal	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Romania	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	San Marino	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Slovak Republic	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Slovenia	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Spain	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Sweden	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Switzerland	09803550,4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Turkey	09803550,4	07/29/2009	Issued

MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Great Britain	09803550.4	07/29/2009	Issued
MDCO-06	Pharmaceutical Compositions And Methods For Producing Low Impurity Concentrations Of The Same	Croatia	09803550.4	07/29/2009	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	United States	13765,613	02/12/2013	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Australia	2011313852	10/10/2011	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Brazil	BR112013008601.7	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Canada	2,814,495	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	China P.R.	201180048865.X	10/10/2011	Rejected (pending appeal)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Egypt	551/2013	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	European Patent Convention	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Eurasian Patent Convention	201390541	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	United Arab Emirates	387/2013	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	United States	13270,804	10/11/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Patent Cooperation Treaty	PCT/US11/58617	10/10/2011	Expired
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	United States	14149,712	02/06/2014	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	United States	61392,294	10/12/2010	Expired
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Hong Kong	14100653.2	10/10/2011	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	India	2874/DELNP/2013	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Japan	2013-533916	10/10/2011	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	South Korea	10-2013-7012057	10/10/2011	Rejected
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	South Korea	10-2016-7006219	3/8/2016	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Mexico	MX/a/2013/004151	10/10/2011	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	New Zealand	610465	10/10/2011	Issued
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Great Britain	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Japan	2014-120354	06/11/2014	Pending
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Mexico	MX/a/2014/014773	12/03/2014	Pending

MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Finland	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	France	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Germany	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Greece	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Hungary	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Ireland	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Austria	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Belgium	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Denmark	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Italy	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Netherlands	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Norway	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Poland	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Portugal	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Spain	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Sweden	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Switzerland	11833207.1	10/10/2011	Allowed (pending opposition)
MDCO-33	Clevidipine Emulsion Formulations Containing Antimicrobial Agents	Turkey	11833207.1	10/10/2011	Allowed (pending opposition)

	dyspnea in AHF patients		8	2013	
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	CA	2,889,584	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	CN	2.0138E+11	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	CO	15-119,412	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	EA	201590825	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	EP	13848937.2 EP2925128	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	IN	4508/DELNP/2015	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	IL	238462	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	JP	2015-539879	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	KR	10-2015-7033890	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	MX	MX/9/2015/005341	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	NZ	708511	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	ZA	2015/03741	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	UA	2015 05170	Oct. 26, 2013	Pending
MDCO-72	Method of controlling blood pressure and reducing dyspnea in AHF patients	VN	1-2015-01859	Oct. 26, 2013	Pending